06/12/2015
Federal Register Notice: FDA has determined the regulatory review period for Pfizer’s Xeljanz (tofacitinib citrate) is 3,947...06/09/2015
Federal Register Notice: FDA’s collection of information entitled “Risk and Benefit Perception Scale Development,&rdqu...06/09/2015
Federal Register Notice: FDA’s collection of information entitled “Evaluation of the Food and Drug Administration&rsqu...06/09/2015
Federal Register Notice: FDA’s collection of information entitled “Prominent and Conspicuous Mark of Manufacturers on ...06/03/2015
Federal Register Notice: FDA’s collection of information entitled, “Disclosure Regarding Additional Risks in Direct-to...06/03/2015
Federal Register Notice: FDA’s collection of information entitled, “Guidance for Industry, Researchers, Patient Groups...06/03/2015
Federal Register Notice: FDA’ s proposed collection of information, “Biosimilars User Fee Cover Sheet; Form FDA 3792,&...06/03/2015
Federal Register Notice: FDA is extending the comment period until 7/20 for a draft standard memorandum of understanding (MOU) ent...